Isoindolinone derivatives having inhibitory activity against T-type calcium channel and method for preparation thereof

1. An isoindolinone compound, represented by the following Chemical Formula 1, or a pharmaceutically acceptable salt thereof:

wherein, R 1 ˜R 5 represent independently a hydrogen atom, a halogen atom, a C 1 ˜C 6 alkoxy, a C 1 ˜C 6 alkyl, a C 1 ˜C 6 haloalkyl, a nitro, a cyano or a hydroxy; and R 6 represents a hydrogen atom, a C 1 ˜C 6 alkyl, or an aryl.

2. The isoindolinone compound or the pharmaceutically acceptable salt according to claim 1 , wherein R 1 ˜R 5 are a hydrogen atom or a halogen atom selected from a group consisting of a fluorine atom, a chlorine atom, a bromine atom, an iodine atom and a combination thereof; and R 6 is a hydrogen atom, a methyl, an ethyl, a normal propyl, an isopropyl, a normal butyl, a tert-butyl or a phenyl.

3. The isoindolinone compound or the pharmaceutically acceptable salt according to claim 1 , wherein the idoindoline compound is selected from a group consisting of:

(1) 2-benzyl-3-oxo-N-(3-(piperidin-1-yl)propyl)isoindoline-5-carboxamide;

(2) 2-(3-fluorobenzyl)-3-oxo-N-(3-(piperidin-1-yl)propypisoindoline-5-carboxamide,

(3) 2-(4-fluorobenzyl) -3-oxo-N-(3-(piperidin-1-yl)propyl)isoindoline-5-carboxamide;

(4) 2-(3-chlorobenzyl) -3-oxo-N-(3-(piperidin-1-yl)propyl)isoindoline-5-carboxamide;

(5) 2-(4-chlorobenzyl)-3-oxo-N-(3-(piperidin-1-yl)propyl)isoindoline-5-carboxamide;

(6) 2-(3-bromobenzyl)-3-oxo-N-(3-(piperidin-1-yl)propyl)isoindoline-5-carboxamide;

(7) 2-(4-bromobenzyl)-3-oxo-N-(3-(piperidin-1-yl)propyl)isoindoline-5-carboxamide;

(8) 2-(3-iodobenzyl)-3-oxo-N-(3-(piperidin-1-yl)propyl)isoindoline-5-carboxamide;

(9) 2-(4-iodobenzyl) -3-oxo-N-(3-(piperidin-1-yl)propyl)isoindoline-5-carboxamide;

(10) 2-benzyl-N-(3-(2-methylpiperidin-1-yl)propyl)-3-oxoisoindoline-5-carboxamide;

(11) 2-(3-fluorobenzyl)-N-(3-(2-methylpiperidin-1-yl)propyl)-3-oxoisoindoline-5-carboxamide;

(12) 2-(4-fluorobenzyl)-N-(3-(2-methylpiperidin-1-yl)propyl)-3-oxoisoindoline-5-carboxamide;

(13) 2-(3-chlorobenzyl)-N-(3-(2-methylpiperidin-1-yl)propyl)-3-oxoisoindoline-5-carboxamide;

(14) 2-(4-chlorobenzyl)-N-(3-(2-methylpiperidin-1-yl)propyl)-3-oxoisoindoline-5-carboxamide;

(15) 2-(3-bromobenzyl)-N-(3-(2-methylpiperidin-1-yl)propyl)-3-oxoisoindoline-5-carboxamide;

(16) 2-(4-bromobenzyl)-N-(3-(2-methylpiperidin-1-yl)propyl)-3-oxoisoindoline-5-carboxamide;

(17) 2 (3-iodobenzyl)-N-(3-(2-methylpiperidin-1-yl)propyl)-3-oxoisoindoline-5-carboxamide;

(18) 2-(4-iodobenzyl)-N-(3-(2-methylpiperidin-1-yl)propyl)-3-oxoisoindoline-5-carboxamide;

(19) 2-benzyl-N-(3-(2-ethylpiperidin-1-yl) propyl) -3oxoisoindoline-5-carboxamide;

(20) N-(3-(2-ethylpiperidin-1-yl)propyl)-2-(3fluorobenzyl)-3-oxoisoindoline-5-carboxamide;

(21) N-(3-(2-ethylpiperidin-1-yl)propyl)-2-(4fluorobenzyl)-3-oxoisoindoline-5-carboxamide;

(22) 2-(3-chlorobenzyl)-N-(3-(2-ethylpiperidin-1-yl)propyl)-3-oxoisoindoline-5-carboxamide;

(23) 2-(4-chlorobenzyl)-N-(3-(2-ethylpiperidin-1-yl)propyl)-3-oxoisoindoline-5-carboxamide;

(24) 2-(3-bromobenzyl)-N-(3-(2-ethylpiperidin-1-yl)propyl)-3-oxoisoindoline-5-carboxamide;

(25) 2-(4-bromobenzyl)-N-(3-(2-ethylpiperidin-1-yl)propyl)-3-oxoisoindoline-5-carboxamide;

(26) N-(3-(2-ethylpiperidin-1-yl)propyl)-2-(3iodobenzyl)-3-oxoisoindoline-5-carboxamide;

(27) N-(3-(2-ethylpiperidin-1-yl)propyl)-2-(4iodobenzyl)-3-oxoisoindoline-5-carboxamide;

(28) 2-benzyl-3-oxo-N-(3-(2-propylpiperidin-1-yl)propyl)isoindoline-5-carboxamide;

(29) 2-(3-fluorobenzyl) -3-oxo-N-(3-(2-propylpiperidin-1-yl)propyl)isoindoline-5-carboxamide,

(30) 2-(4-fluorobenzyl)-3-oxo-N-(3-(2-propylpiperidin-1-yl)propyl)isoindoline-5-carboxamide;

(31) 2-(3-chlorobenzyl)-3-oxo-N-(3-(2-propylpiperidin-1-yl)propyl)isoindoline-5-carboxamide;

(32) 2-(4-chlorobenzyl)-3-oxo-N-(3-(2-propylpiperidin-1-yl)propyl)isoindoline-5-carboxamide;

(33) 2-(3-bromobenzyl)-3-oxo-N-(3-(2-propylpiperidin-1-yl)propyl)isoindoline-5-carboxamide;

(34) 2-(4-bromobenzyl) -3-oxo-N-(3-(2-propylpiperidin-1-yl)propyl)isoindoline-5-carboxamide;

(35) 2-(3-iodobenzyl)-3-oxo-N-(3-(2-propylpiperidin-1-yl)propyl)isoindoline-5-carboxamide;

(36) 2-(4-iodobenzyl)-3-oxo-N-(3-(2-propylpiperidin-1-yl)propyl)isoindoline-5-carboxamide;

(37) 2-benzyl-N-(3-(2-isopropylpiperidin-1-yl)propyl)-3-oxoisoindoline-5-carboxamide,

(38) 2-(3-fluorobenzyl)-N-(3-(2-isopropylpiperidin-1-yl)propyl)-3-oxoisoindoline-5-carboxamide;

(39) 2-(4-fluorobenzyl) -N-(3-(2-isopropylpiperidin-1-yl)propyl)-3-oxoisoindoline-5-carboxamide;

(40) 2-(3-chlorobenzyl)-N-(3-(2-isopropylpiperidin-1-yl)propyl)-3-oxoisoindoline-5-carboxamide;

(41) 2-(4-chlorobenzyl)-N-(3-(2-isopropylpiperidin-1-yl)propyl)-3-oxoisoindoline-5-carboxamide;

(42) 2-(3-bromobenzyl)-N-(3-(2-isopropylpiperidin-1-yl)propyl)-3-oxoisoindoline-5-carboxamide;

(43) 2-(4-bromobenzyl)-N-(3-(2-isopropylpiperidin-1- yl)propyl)-3-oxoisoindoline-5-carboxamide;

(44) 2-(3-iodobenzyl) -N-(3-(2-isopropylpiperidin-1-yl)propyl)-3-oxoisoindoline-5-carboxamide;

(45) 2-(4-iodobenzyl)-N-(3-(2-isopropylpiperidin-1-yl)propyl)-3-oxoisoindoline-5-carboxamide;

(46) 2-benzyl-N-(3-(2-butylpiperidin-1-yl)propyl)-3-oxoisoindoline-5-carboxamide;

(47) N-(3-(2-butylpiperidin-1-yl)propyl)-2-(3-fluorobenzyl)-3-oxoisoindoline-5-carboxamide;

(48) N-(3-(2-butylpiperidin-tyl)propyl)-2-(4-fluorobenzyl)-3-oxoisoindoline-5-carboxamide;

(49) N-(3-(2-butylpiperidin-1-yl)propyl)-2-(3-chlorobenzyl)-3-oxoisoindoline-5-carboxamide;

(50) N-(3-(2-butylpiperidin-1-yl)propyl)-2-(4-chlorobenzyl)-3-oxoisoindoline-5-carboxamide;

(51) 2-(3-bromobenzyl)-N-(3-(2-butylpiperidin-1-yl)propyl)-3-oxoisoindoline-5-carboxamide;

(52) 2-(4-bromobenzyl)-N-(3-(2-butylpiperidin-1-yl)propyl)-3-oxoisoindoline-5-carboxamide;

(53) N-(3-(2-butylpiperidin-1-yl)propyl)-2-(3iodobenzyl)-3-oxoisoindoline-5-carboxamide;

(54) N-(3-(2-butylpiperidin-1-yl)propyl)-2-(4iodobenzyl)-3-oxoisoindoline-5-carboxamide;

(55) 2-benzyl-3-oxo-N-(3-(2-phenylpiperidin-1-yl)propyl)isoindoline-5-carboxamide;

(56) 2-(3-fluorobenzyl)-3-oxo-N-(3-(2-phenylpiperidin-1-yl)propyl)isoindoline-5-carboxamide;

(57) 2-(4-fluorobenzyl)-3-oxo-N-(3-(2-phenylpiperidin-1-yl)propyl)isoindoline-5-carboxamide,

(58) 2-(3-chlorobenzyl)-3-oxo-N-(3-(2-phenylpiperidin-1-yl)propyl)isoindoline-5-carboxamide;

(59) 2-(4-chlorobenzyl)-3-oxo-N-(3-(2-phenylpiperidin-1-yl)propyl)isoindoline-5-carboxamide;

(60) 2-(3-bromobenzyl)-3-oxo-N-(3-(2-phenylpiperidin-1-yl)propyl)isoindoline-5-carboxamide;

(61) 2-(4-bromobenzyl)-3-oxo-N-(3-(2-phenylpiperidin-1-yl)propyl)isoindoline-5-carboxamide;

(62) 2-(3-iodobenzyl)-3-oxo-N-(3-(2-phenylpiperidin-1-yl)propyl)isoindoline-5-carboxamide; and

(63) 2-(4-iodobenzyl)-3-oxo-N-(3-(2-phenylpiperidin-1-yl)propyl)isoindoline-5-carboxamide.

4. A method for preparing the isoindolinone compound of Chemical Formula 1, as illustrated in the following Reaction Scheme I, comprising:

converting 3-bromo-4-methylbenzoic acid of Chemical Formula 2 into aryl lithium using methylmagnesium bromide (CH 3 MgBr) and n-butyl lithium under nitrogen atmosphere, followed by the carboxylation of the aryl lithium with carbon dioxide into a dicarboxylic acid of Chemical Formula 3 (Step 1);

esterifying the dicarboxylic acid of Chemical Formula 3 with an alkyl to give a diester compound of Chemical Formula 4 (Step 2);

brominating the diester of Chemical Formula 4 into a bromine compound of Chemical Formula 5 (Step 3);

subjecting the brominated compound of Chemical Formula 5 to SN 2 -type alkylation with a benzyleamine compound of Chemical Formula 6, followed by cyclization to afford an isoindolinone backbone compound of Chemical Formula 7 (Step 4);

hydrolyzing the compound of Chemical Formula 7 to an isoindolinone carboxylic acid derivative of Chemical Formula 8 (Step 5); and

amide-coupling the isoindolinone carboxylic acid of Chemical Formula 8 with a piperidinyl propylamine compound of 5 Chemical Formula 9 to afford the isoindolinone compound of Chemical Formula 1 (Step 6)

wherein R 1 ˜R 6 are as defined in claim 1 .

5. The isoindolinone compound or the pharmaceutically acceptable salt according to claim 1 , wherein the pharmaceutically acceptable salt is formed from a free acid.

6. The isoindolinone compound or the pharmaceutically acceptable salt according to claim 5 , wherein the free acid is selected from the group consisting of hydrochloric acid, bromic acid, sulfonic acid, aminosulfuric acid, phosphoric acid, nitric acid, acetic acid, propionic acid, succinic acid, glycolic acid, stearic acid, lactic acid tartaric acid, citric acid, ρ-toluenesulfonic acid, and methanesulfonic acid.